Argos Therapeutics Inc (NASDAQ:ARGS) had its price objective trimmed by Stifel Nicolaus to $1.20 in a research report released on Friday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on ARGS. Zacks Investment Research upgraded shares of Argos Therapeutics from a hold rating to a buy rating and set a $6.00 price target on the stock in a research note on Monday, January 16th. FBR & Co reiterated a buy rating and issued a $13.00 price target on shares of Argos Therapeutics in a research note on Tuesday, January 17th. Needham & Company LLC reiterated a buy rating and issued a $10.00 price target on shares of Argos Therapeutics in a research note on Friday, December 9th. Finally, JMP Securities lowered shares of Argos Therapeutics from an outperform rating to a market perform rating in a research note on Wednesday, February 22nd. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $8.03.
Shares of Argos Therapeutics (NASDAQ:ARGS) traded down 18.7600% on Friday, hitting $0.8124. 763,970 shares of the stock were exchanged. Argos Therapeutics has a one year low of $0.75 and a one year high of $13.97. The firm’s market capitalization is $33.51 million. The company has a 50-day moving average price of $2.93 and a 200-day moving average price of $4.34.
Your IP Address:
A number of large investors have recently modified their holdings of ARGS. State Street Corp raised its stake in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock valued at $870,000 after buying an additional 18,625 shares during the last quarter. Wasatch Advisors Inc. raised its stake in shares of Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock valued at $16,047,000 after buying an additional 840,260 shares during the last quarter. Finally, Sanders Morris Harris Inc. raised its stake in shares of Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock valued at $1,201,000 after buying an additional 126,475 shares during the last quarter. Hedge funds and other institutional investors own 15.25% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/argos-therapeutics-inc-args-price-target-cut-to-1-20-by-analysts-at-stifel-nicolaus/1709165.html
Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.